Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm autoimmune hemolytic anemia and IgG4-related disease.

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for two ...

The FDA granted orphan drug designation to Sanofi’s pipeline candidate, rilzabrutinib, for the treatment of two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease ...

Sanofi (NASDAQ:SNY) announced today that its investigational drug, rilzabrutinib, has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for two rare diseases: warm ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug designation.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine ...